Kyverna Therapeutics
NASDAQ: KYTXEmeryville, US · Delaware corporation · 1 known investors
Biotech
Founders & leadership
BK
Brian KotzinNamed on SEC filing
IC
Ian ClarkNamed on SEC filing
RJ
Ryan JonesNamed on SEC filing
KW
Karen WalkerNamed on SEC filing
PM
Peter MaagNamed on SEC filing
JC
James ChungNamed on SEC filing
DS
Dan SpiegelmanNamed on SEC filing
BS
Beth SpiegelmanNamed on SEC filing
FC
Fred CohenNamed on SEC filing
SL
Steve LiapisNamed on SEC filing
DB
Dominic BorieNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$152M disclosed across 1 round · 2021
▶$152MraisedNov 2023 · 24 investors · BiotechnologyRule 506(b)
▶$152MraisedNov 2023 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian KotzinDirector
- Ian ClarkDirector
- Ryan JonesExecutive Officer
- Karen WalkerExecutive Officer
- Peter MaagExecutive Officer, Director
- James ChungExecutive Officer
- Dan SpiegelmanDirector
- Beth SpiegelmanDirector
- Fred CohenDirector
- Steve LiapisDirector
- Dominic BorieExecutive Officer
- Offering amount
- $152M
- Amount sold
- $152M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Kyverna Therapeutics's investors?
- Kyverna Therapeutics's investors include Bain Capital Life Sciences.
- How much funding has Kyverna Therapeutics raised?
- Kyverna Therapeutics has disclosed $152M raised across 1 round.
- Where is Kyverna Therapeutics headquartered?
- Kyverna Therapeutics is headquartered in Emeryville, US.